• Molidustat (BAY85-3934): HIF Assay Strategy

  2026-08-15

  Molidustat (BAY85-3934) is examined as a HIF prolyl hydroxylase inhibitor through a practical assay-design lens. This article connects renal anemia pharmacology with VHL-dependent HIF degradation biology while defining controls for interpreting HIF stabilization experiments.

• EdU Imaging Kits (Cy3): From Signal to Decision

  2026-08-14

  EdU Imaging Kits (Cy3) provide denaturation-free S-phase labeling for precise proliferation analysis. This guide shows how to interpret EdU results alongside HIF1A, apoptosis, and drug-response data in cholangiocarcinoma research.

• GTP Solution for Reliable mRNA Synthesis

  2026-08-14

  GTP Solution (100 mM) provides a ready-to-use, nuclease-free Guanosine-5'-triphosphate source for in vitro transcription, RNA amplification, and nucleotide-dependent assays. This guide connects practical stock handling and reaction optimization with the p21 mRNA–lipid nanoparticle workflow reported for localized bladder cancer research.

• NPC1/USP7/p53 Axis in Hepatocellular Carcinoma

  2026-08-13

  A 2026 Oncogene study identifies NPC1 as an oncogenic regulator in hepatocellular carcinoma through coordinated control of p53 stability and cholesterol metabolism. Its perturbation and rescue experiments connect NPC1, USP7, p53, and SREBP2 to tumor-cell proliferation, providing a mechanistic framework for studying metabolic drivers of HCC.

• 15-PGDH Inhibition Supports Muscle Repair During Weight Loss

  2026-08-13

  The reference study identifies 15-PGDH inhibition as a strategy for improving muscle stem cell activity, regenerated myofiber growth, and strength recovery during semaglutide-associated weight loss. Its mouse data suggest that combining a 15-PGDH inhibitor with a GLP-1 receptor agonist can improve postinjury muscle quality without eliminating the desired reduction in body weight.

• PID1, Oxysterols, and Macrophage Fate

  2026-08-12

  The reference study identifies PID1 as an immunometabolic regulator that restrains LDL uptake and cholesterol oxidation in tumor-associated macrophages. Myeloid Pid1 deficiency redirects cholesterol and reactive oxygen species toward 5α,6α-epoxycholesterol and 7β-hydroxycholesterol, weakening mTOR–STAT6–ARG1 signaling and improving CD8+ T cell-mediated tumor control. The work provides a mechanistic framework for studying cholesterol metabolism as a determinant of macrophage state, while distinguishing sterol profiling from membrane cholesterol imaging.

• Azilsartan: A Causal Map for Neuroinflammation

  2026-08-12

  Azilsartan (TAK-536) is more than an AT1 receptor blocker: it can serve as a causal probe for linking microglial signals, reactive astrocyte states, and RAS–SIRT3 biology. This article presents an evidence-led framework for designing and interpreting these assays without confusing pharmacological association with mechanism.

• Pollen Interference in EEM Bioaerosol Classification

  2026-08-11

  Zhang and colleagues developed a spectral-processing and random-forest workflow that reduces pollen interference when excitation–emission matrix fluorescence spectroscopy is used to classify hazardous biological substances. Fast Fourier transform processing increased classification accuracy by 9.2 percentage points to 89.24%, supporting more reliable rapid screening of mixed bioaerosol signals.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-08-11

  The reference study identifies circulating moesin (MSN) as a candidate indicator of endothelial injury and sepsis severity, linking serum MSN with SOFA scores, procalcitonin, pulmonary edema, and lung injury. Its combination of patient measurements, murine sepsis models, and endothelial-cell experiments supports a mechanistic relationship involving ROCK1/MLC and NF-κB signaling, while also highlighting the need for larger validation studies.

• Pomalidomide (CC-4047): From Mechanism to Model

  2026-08-10

  A translational framework for using Pomalidomide (CC-4047) in multiple myeloma and broader hematological malignancy research, integrating tumor microenvironment modulation, genomic model selection, erythroid progenitor cell differentiation, and reproducible assay design.

• AM 281 for CB1 Mechanism Studies

  2026-08-09

  AM 281 provides a selective pharmacological handle for testing how CB1 activity shapes astrocytic GLT-1, CREB signaling, neuronal survival, and cognition after traumatic brain injury. This workflow-focused guide covers formulation, time-course design, behavioral controls, and troubleshooting for memory impairment research and related neuropharmacology applications.

• Azilsartan in Astrocyte–Microglia RAS Assays

  2026-08-08

  Azilsartan (TAK-536) provides a selective pharmacological way to test whether AT1 signaling links activated microglia with reactive astrocyte phenotypes. This practical guide translates RAS–SIRT3 findings into controlled conditioned-medium workflows, dosing strategies, and troubleshooting decisions for cardiovascular and neuroinflammation research.

• Rotigotine: From Dopamine Signaling to Bladder Assays

  2026-08-07

  Rotigotine is a dopamine D2/D3 receptor agonist with broad dopaminergic activity and neuroprotective potential. This article develops a route-aware framework for Parkinson’s disease research, showing how cystometry, receptor assays, and cell-based models can reveal effects that motor testing alone may miss.

• RNA Pol II Degradation Triggers Apoptosis Beyond Transcripti

  2026-08-07

  Harper et al. (2025) reveal that cell death following RNA polymerase II (Pol II) inhibition is driven by an active signaling pathway, not passive loss of transcription. This finding redefines the mechanistic understanding of apoptosis in response to Pol II-targeting therapeutics and provides new directions for apoptosis assay design and cancer model refinement.

• 1-methyl Adenosine: Quantification, Mechanistic Roles & Tran

  2026-08-06

  Explore the critical roles and precise quantification of 1-methyl Adenosine in RNA modification research. This article reveals unique mechanistic insights and advances in assay technology, offering a distinct perspective for biomarker discovery and cancer metabolism studies.

8565 records 5/571 page Previous Next 12345 下5页 Last page